Annovis Bio, Inc. (ANVS)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
As of 01:36PM EDT. Market open.
| Previous close | 13.60 |
| Open | 13.71 |
| Bid | 16.06 x 1200 |
| Ask | 16.31 x 900 |
| Day's range | 13.71 - 16.74 |
| 52-week range | 5.42 - 22.49 |
| Volume | |
| Avg. volume | 226,708 |
| Market cap | 179.925M |
| Beta (5Y monthly) | 1.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.23 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 35.40 |
ZacksWall Street Analysts Believe Annovis Bio (ANVS) Could Rally 197.98%: Here's is How to Trade
The mean of analysts' price targets for Annovis Bio (ANVS) points to a 198% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ZacksVertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies.
ZacksVertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug
Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.
© 2024 Yahoo. All rights reserved.